A double-blind vehicle-controlled study of R 68 151 in psoriasis: A topical 5-lipoxygenase inhibitor
- 31 May 1990
- journal article
- clinical trial
- Published by Elsevier in Journal of the American Academy of Dermatology
- Vol. 22 (5), 751-755
- https://doi.org/10.1016/0190-9622(90)70103-o
Abstract
No abstract availableKeywords
This publication has 9 references indexed in Scilit:
- The in vitro 5‐lipoxygenase and cyclo‐oxygenase inhibitor L‐652,343 does not inhibit 5‐lipoxygenase in vivo in human skin.British Journal of Clinical Pharmacology, 1988
- Proinflammatory properties of unsaturated fatty acids and their monohydroxy metabolitesProstaglandins, 1985
- The Responses of Normal and Psoriatic Skin to Single and Multiple Topical Applications of Leukotriene B4Journal of Investigative Dermatology, 1985
- Leukotrienes C4 and D4 psoriatic skin lesionsProstaglandins, 1985
- The Release of Leukotriene B4-like Material in Biologically Active Amounts from the Lesional Skin of patients with PsoriasisJournal of Investigative Dermatology, 1984
- Production of Intraepidermal Microabscesses by Topical Application of Leukotriene B4Journal of Investigative Dermatology, 1984
- CHEMOTACTIC LEUKOTRIENES IN PSORIASISThe Lancet, 1982
- Mediators of Immediate Hypersensitivity Derived from Arachidonic AcidNew England Journal of Medicine, 1980
- Increased concentrations of nonesterified arachidonic acid, 12L-hydroxy-5,8,10,14-eicosatetraenoic acid, prostaglandin E2, and prostaglandin F2alpha in epidermis of psoriasis.Proceedings of the National Academy of Sciences, 1975